Barclays
HUMA icon

Barclays’s Humacyte HUMA Stock Holding History

Barclays’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31K Sell
39,680
-467
-1% -$433 ﹤0.01% 4477
2026
Q1 		$24.4K Sell
40,147
-689,322
-94% -$717K ﹤0.01% 4533
2025
Q4 		$701K Buy
729,469
+546,491
+299% +$774K ﹤0.01% 3664
2025
Q3 		$318K Sell
182,978
-260,001
-59% -$509K ﹤0.01% 4062
2025
Q2 		$926K Buy
442,979
+248,350
+128% +$477K ﹤0.01% 3394
2025
Q1 		$332K Sell
194,629
-31,637
-14% -$119K ﹤0.01% 3770
2024
Q4 		$1.14M Sell
226,266
-10,476
-4% -$51.8K ﹤0.01% 3290
2024
Q3 		$1.29M Buy
236,742
+151,458
+178% +$999K ﹤0.01% 3185
2024
Q2 		$409K Buy
85,284
+18,319
+27% +$95.3K ﹤0.01% 3159
2024
Q1 		$208K Sell
66,965
-30,222
-31% -$102K ﹤0.01% 4102
2023
Q4 		$276K Buy
97,187
+73,399
+309% +$188K ﹤0.01% 4267
2023
Q3 		$69.7K Sell
23,788
-47,055
-66% -$156K ﹤0.01% 3724
2023
Q2 		$203K Buy
70,843
+26,591
+60% +$95.9K ﹤0.01% 3228
2023
Q1 		$137K Buy
44,252
+14,145
+47% +$40.2K ﹤0.01% 4006
2022
Q4 		$63.5K Buy
30,107
+15,036
+100% +$45.6K ﹤0.01% 4455
2022
Q3 		$49K Sell
15,071
-137
-0.9% -$525 ﹤0.01% 3785
2022
Q2 		$49K Buy
15,208
+647
+4% +$3.6K ﹤0.01% 4042
2022
Q1 		$103K Buy
+14,561
New +$84.8K ﹤0.01% 3764

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's HUMA Position: Q2 2026 in Review

Barclays reduced its Humacyte (HUMA) stake by 1.2% in Q2 2026, selling an estimated $433 and leaving 39,680 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #4477.

Barclays first reported a position in HUMA in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.29M in Q3 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Barclays held 39,680 shares of Humacyte worth $31K as of Q2 2026.
  • Barclays sold 467 Humacyte shares in Q2 2026, an estimated $433.
  • Humacyte made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4477 holding.
  • Barclays first reported a position in Humacyte in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Humacyte position peaked at $1.29M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.